Christopher L Bowlus

List of Publications by Year
in descending order

217	11,075	28190 55	34900 98
papers	citations	h-index	g-index

225	225	225	10012
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. New England Journal of Medicine, 2016, 375, 631-643.	13.9	817
2	Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Current Medical Research and Opinion, 2008, 24, 275-286.	0.9	657
3	Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases. Hepatology, 2019, 69, 394-419.	3.6	507
4	Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis. Gastroenterology, 2017, 152, 1975-1984.e8.	0.6	355
5	Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. Nature Genetics, 2013, 45, 670-675.	9.4	339
6	Primary biliary cirrhosis. Lancet, The, 2011, 377, 1600-1609.	6.3	294
7	Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Current Medical Research and Opinion, 2008, 24, 275-286.	0.9	280
8	Liver-targeted and peripheral blood alterations of regulatory T cells in primary biliary cirrhosis. Hepatology, 2006, 43, 729-737.	3.6	274
9	Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: An interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. Clinical Therapeutics, 2007, 29, 139-153.	1.1	272
10	Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease. Nature Genetics, 2017, 49, 269-273.	9.4	230
11	Biliary apotopes and anti-mitochondrial antibodies activate innate immune responses in primary biliary cirrhosis. Hepatology, 2010, 52, 987-998.	3.6	194
12	The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GSâ€9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis. Hepatology, 2019, 70, 788-801.	3.6	180
13	De novo nonalcoholic fatty liver disease after liver transplantation. Liver Transplantation, 2007, 13, 844-847.	1.3	168
14	IL-12/Th1 and IL-23/Th17 biliary microenvironment in primary biliary cirrhosis: Implications for therapy. Hepatology, 2014, 59, 1944-1953.	3.6	168
15	IL-2 receptor alpha deficiency and features of primary biliary cirrhosis. Journal of Autoimmunity, 2006, 27, 50-53.	3.0	162
16	DMT1 gene expression and cadmium absorption in human absorptive enterocytes. Toxicology Letters, 2001, 122, 171-177.	0.4	143
17	The diagnosis of primary biliary cirrhosis. Autoimmunity Reviews, 2014, 13, 441-444.	2.5	133
18	Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. Hepatology, 2012, 55, 512-521.	3.6	130

#	Article	IF	Citations
19	Seladelpar (MBX-8025), a selective PPAR-Î´ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study. The Lancet Gastroenterology and Hepatology, 2017, 2, 716-726.	3.7	126
20	Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the Disease. Hepatology, 2019, 69, 684-698.	3.6	121
21	Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study. The Lancet Gastroenterology and Hepatology, 2019, 4, 445-453.	3.7	116
22	A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis. Journal of Hepatology, 2020, 73, 94-101.	1.8	111
23	T cell immunity in autoimmune hepatitis. Autoimmunity Reviews, 2005, 4, 315-321.	2.5	108
24	Transforming growth factor Î² (TGF-Î²) and autoimmunity. Autoimmunity Reviews, 2005, 4, 450-459.	2.5	108
25	Etiopathogenesis of autoimmune hepatitis. Journal of Autoimmunity, 2018, 95, 133-143.	3.0	105
26	The geoepidemiology of autoimmune intestinal diseases. Autoimmunity Reviews, 2010, 9, A372-A378.	2.5	99
27	Evaluation of indeterminate biliary strictures. Nature Reviews Gastroenterology and Hepatology, 2016, 13, 28-37.	8.2	99
28	Lymphocyte recruitment and homing to the liver in primary biliary cirrhosis and primary sclerosing cholangitis. Seminars in Immunopathology, 2009, 31, 309-322.	2.8	98
29	Cloning and analysis of the promotor region of the human fibronectin gene.. Proceedings of the National Academy of Sciences of the United States of America, 1987, 84, 1876-1880.	3.3	97
30	Costs of Hepatitis C. Archives of Internal Medicine, 2001, 161, 2231.	4.3	97
31	The immunobiology of primary sclerosing cholangitis. Seminars in Immunopathology, 2009, 31, 383-397.	2.8	92
32	The prevalence, incidence and natural history of primary sclerosing cholangitis in an ethnically diverse population. BMC Gastroenterology, 2011, 11, 83.	0.8	88
33	The challenges of primary biliary cholangitis: What is new and what needs to be done. Journal of Autoimmunity, 2019, 105, 102328.	3.0	86
34	The role of iron in T cell development and autoimmunity. Autoimmunity Reviews, 2003, 2, 73-78.	2.5	83
35	Factors associated with advanced liver disease in adults with alpha1-antitrypsin deficiency. Clinical Gastroenterology and Hepatology, 2005, 3, 390-396.	2.4	83
36	IL-35 and Autoimmunity: a Comprehensive Perspective. Clinical Reviews in Allergy and Immunology, 2015, 49, 327-332.	2.9	78

#	Article	IF	Citations
37	B Cells Suppress the Inflammatory Response in a Mouse Model of Primary Biliary Cirrhosis. Gastroenterology, 2009, 136, 1037-1047.	0.6	76
38	Serum microRNAs as novel biomarkers for primary sclerosing cholangitis and cholangiocarcinoma. Clinical and Experimental Immunology, 2016, 185, 61-71.	1.1	75
39	Increasing Prevalence of Primary Biliary Cholangitis and Reduced Mortality With Treatment. Clinical Gastroenterology and Hepatology, 2018, 16, 1342-1350.e1.	2.4	73
40	The immunobiology of primary sclerosing cholangitis. Autoimmunity Reviews, 2005, 4, 137-143.	2.5	71
41	Ongoing activation of autoantigen-specific B cells in primary biliary cirrhosis. Hepatology, 2014, 60, 1708-1716.	3.6	67
42	Iron supplementation during infancyâ€"effects on expression of iron transporters, iron absorption, and iron utilization in rat pups. American Journal of Clinical Nutrition, 2003, 78, 1203-1211.	2.2	66
43	Antiâ€kelchâ€like 12 and antiâ€hexokinase 1: novel autoantibodies in primary biliary cirrhosis. Liver International, 2015, 35, 642-651.	1.9	66
44	Primary sclerosing cholangitis in genetically diverse populations listed for liver transplantation: Unique clinical and human leukocyte antigen associations. Liver Transplantation, 2010, 16, 1324-1330.	1.3	65
45	T cell immunity and graft-versus-host disease (GVHD). Autoimmunity Reviews, 2006, 5, 1-9.	2.5	63
46	Impaired homocysteine transsulfuration is an indicator of alcoholic liver disease. Journal of Hepatology, 2010, 53, 551-557.	1.8	63
47	S-adenosyl-L-methionine Treatment for Alcoholic Liver Disease: A Double-Blinded, Randomized, Placebo-Controlled Trial. Alcoholism: Clinical and Experimental Research, 2011, 35, 1960-1965.	1.4	63
48	Long-Term Obeticholic Acid Therapy Improves Histological Endpoints in Patients With Primary Biliary Cholangitis. Clinical Gastroenterology and Hepatology, 2020, 18, 1170-1178.e6.	2.4	61
49	Epithelial cell specificity and apotope recognition by serum autoantibodies in primary biliary cirrhosis. Hepatology, 2011, 54, 196-203.	3.6	60
50	AGA Clinical Practice Update on Surveillance for Hepatobiliary Cancers in Patients With Primary Sclerosing Cholangitis: Expert Review. Clinical Gastroenterology and Hepatology, 2019, 17, 2416-2422.	2.4	60
51	Functional and molecular responses of human intestinal Caco-2 cells to iron treatment. American Journal of Clinical Nutrition, 2000, 72, 770-775.	2.2	59
52	Liver hepcidin mRNA correlates with iron stores, but not inflammation, in patients with chronic hepatitis C. Journal of Clinical Gastroenterology, 2005, 39, 71-4.	1.1	59
53	DMT1 and FPN1 expression during infancy: developmental regulation of iron absorption. American Journal of Physiology - Renal Physiology, 2003, 285, G1153-G1161.	1.6	58
54	Revisiting Hereditary Hemochromatosis: Current Concepts and Progress. American Journal of Medicine, 2006, 119, 391-399.	0.6	58

#	Article	IF	Citations
55	Antimitochondrial antibody heterogeneity and the xenobiotic etiology of primary biliary cirrhosis. Hepatology, 2013, 57, 1498-1508.	3.6	58
56	Common Variable Immunodeficiency and Liver Involvement. Clinical Reviews in Allergy and Immunology, 2018, 55, 340-351.	2.9	58
57	A Randomized, Controlled, Phase 2 Study of Maralixibat in the Treatment of Itching Associated With Primary Biliary Cholangitis. Hepatology Communications, 2019, 3, 365-381.	2.0	58
58	Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology, 2020, 18, 179-187.e6.	2.4	57
59	Myeloperoxidase-positive inflammatory cells participate in bile duct damage in primary biliary cirrhosis through nitric oxide-mediated reactions. Hepatology, 2003, 38, 1018-1025.	3.6	53
60	Fine phenotypic and functional characterization of effector cluster of differentiation 8 positive T cells in human patients with primary biliary cirrhosis. Hepatology, 2011, 54, 1293-1302.	3.6	53
61	Diagnosis and classification of primary sclerosing cholangitis. Autoimmunity Reviews, 2014, 13, 445-450.	2.5	53
62	Cloning of a Novel MHC-Encoded Serine Peptidase Highly Expressed by Cortical Epithelial Cells of the Thymus. Cellular Immunology, 1999, 196, 80-86.	1.4	52
63	The evolution of natural history of primary sclerosing cholangitis. Current Opinion in Gastroenterology, 2017, 33, 71-77.	1.0	52
64	Differential gene expression between flat adenoma and normal mucosa in the colon in a microarray analysis. Journal of Gastroenterology, 2006, 41, 1053-1063.	2.3	51
65	Increasing Hepatitis B Screening for Hmong Adults: Results from a Randomized Controlled Community-Based Study. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 782-791.	1.1	51
66	The modulation of co-stimulatory molecules by circulating exosomes in primary biliary cirrhosis. Cellular and Molecular Immunology, 2017, 14, 276-284.	4.8	51
67	Incidence and Risk Factors for Hepatocellular Carcinoma in Primary Biliary Cirrhosis. Clinical Reviews in Allergy and Immunology, 2015, 48, 132-141.	2.9	50
68	Cholangiocarcinoma in Patients with Primary Sclerosing Cholangitis (PSC): a Comprehensive Review. Clinical Reviews in Allergy and Immunology, 2020, 58, 134-149.	2.9	49
69	Racial/ethnic disparities in hepatocellular carcinoma treatment and survival in California, 1988-2012. World Journal of Gastroenterology, 2016, 22, 8584.	1.4	48
70	Changes in plasma ghrelin levels, gastric ghrelin production, and body weight after Helicobacter pylori cure. Journal of Gastroenterology, 2006, 41, 954-961.	2.3	47
71	A Transcription Map of the Major Histocompatibility Complex (MHC) Class I Region. Genomics, 1996, 36, 70-85.	1.3	46
72	Factors Associated With Prevalence and Treatment of Primary Biliary Cholangitis in United States Health Systems. Clinical Gastroenterology and Hepatology, 2018, 16, 1333-1341.e6.	2.4	42

#	Article	IF	Citations
73	Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis. Gut, 2018, 67, 1517-1524.	6.1	42
74	Human gamma-aminobutyric acid B receptor gene: complementary DNA cloning, expression, chromosomal location, and genomic organization. Biological Psychiatry, 1998, 44, 659-666.	0.7	41
75	Electronic Messages Increase Hepatitis B Screening in At-Risk Asian American Patients: A Randomized, Controlled Trial. Digestive Diseases and Sciences, 2013, 58, 807-814.	1.1	41
76	Anti-CD40 ligand monoclonal antibody delays the progression of murine autoimmune cholangitis. Clinical and Experimental Immunology, 2013, 174, 364-371.	1.1	41
77	Therapeutic trials of biologics in primary biliary cholangitis: An open label study of abatacept and review of the literature. Journal of Autoimmunity, 2019, 101, 26-34.	3.0	40
78	Effect of Iron Treatment on Nickel Absorption and Gene Expression of the Divalent Metal Transporter (DMT1) by Human Intestinal Caco-2 Cells. Basic and Clinical Pharmacology and Toxicology, 2003, 92, 121-124.	0.0	39
79	Primary sclerosing cholangitis: A review and update. Liver Research, 2017, 1, 221-230.	0.5	38
80	The Clinical Significance of GP73 in Immunologically Mediated Chronic Liver Diseases: Experimental Data and Literature Review. Clinical Reviews in Allergy and Immunology, 2018, 54, 282-294.	2.9	36
81	A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis. Journal of Hepatology, 2022, 77, 353-364.	1.8	36
82	Obeticholic acid for the treatment of primary biliary cholangitis in adult patients: clinical utility and patient selection. Hepatic Medicine: Evidence and Research, 2016, Volume 8, 89-95.	0.9	35
83	New Therapies for Primary Biliary Cirrhosis. Clinical Reviews in Allergy and Immunology, 2015, 48, 263-272.	2.9	34
84	Primary biliary cholangitis: 2021 practice guidance update from the American Association for the Study of Liver Diseases. Hepatology, 2022, 75, 1012-1013.	3.6	34
85	Community-Based Services to Improve Testing and Linkage to Care Among Nonâ€“U.S.-Born Persons with Chronic Hepatitis B Virus Infection â€” Three U.S. Programs, October 2014â€“September 2017. Morbidity and Mortality Weekly Report, 2018, 67, 541-546.	9.0	33
86	Anti-Mitochondrial Antibodyâ€“Negative Primary Biliary Cirrhosis. Clinics in Liver Disease, 2008, 12, 173-185.	1.0	32
87	Epigenomic signatures in liver and blood of Wilson disease patients include hypermethylation of liver-specific enhancers. Epigenetics and Chromatin, 2019, 12, 10.	1.8	32
88	IRON HOMEOSTASIS DURING TRANSFUSIONAL IRON OVERLOAD IN Î²-THALASSEMIA AND SICKLE CELL DISEASE: Changes in Iron Regulatory Protein, Hepcidin, and Ferritin Expression. Pediatric Hematology and Oncology, 2007, 24, 237-243.	0.3	31
89	Advances in pharmacotherapy for primary biliary cirrhosis. Expert Opinion on Pharmacotherapy, 2015, 16, 633-643.	0.9	31
90	Autotaxin, Pruritus and Primary Biliary Cholangitis (PBC). Autoimmunity Reviews, 2016, 15, 795-800.	2.5	31

#	Article	IF	Citations
91	Seladelpar improved measures of pruritus, sleep, and fatigue and decreased serum bile acids in patients with primary biliary cholangitis. Liver International, 2022, 42, 112-123.	1.9	31
92	Epidemiology, Natural History, and Outcomes of Primary Sclerosing Cholangitis: A Systematic Review of Population-based Studies. Clinical Gastroenterology and Hepatology, 2022, 20, 1687-1700.e4.	2.4	31
93	Transcription Profile ofHelicobacter pyloriin the Human Stomach Reflects Its Physiology In Vivo. Journal of Infectious Diseases, 2004, 190, 946-956.	1.9	30
94	Effect of penicillamine and zinc on iron metabolism in Wilson's disease. Scandinavian Journal of Gastroenterology, 2007, 42, 1495-1500.	0.6	30
95	Quality of life and everyday activities in patients with primary biliary cirrhosis. Hepatology, 2007, 46, 1836-1843.	3.6	30
96	Antimitochondrial Antibody Recognition and Structural Integrity of the Inner Lipoyl Domain of the E2 Subunit of Pyruvate Dehydrogenase Complex. Journal of Immunology, 2013, 191, 2126-2133.	0.4	30
97	T cell clonal expansions detected in patients with primary biliary cirrhosis express CX3CR1. Journal of Autoimmunity, 2011, 37, 71-78.	3.0	29
98	The Immunophysiology and Apoptosis of Biliary Epithelial Cells: Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis. Clinical Reviews in Allergy and Immunology, 2012, 43, 230-241.	2.9	28
99	O168 THE FIRST PRIMARY BILIARY CIRRHOSIS (PBC) PHASE 3 TRIAL IN TWO DECADES â€“ AN INTERNATIONAL STUDY OF THE FXR AGONIST OBETICHOLIC ACID IN PBC PATIENTS. Journal of Hepatology, 2014, 60, S525-S526.	1.8	28
100	Primary Sclerosing Cholangitis. Clinics in Liver Disease, 2016, 20, 67-77.	1.0	28
101	The Management of Autoimmune Hepatitis Patients with Decompensated Cirrhosis: Real-World Experience and a Comprehensive Review. Clinical Reviews in Allergy and Immunology, 2017, 52, 424-435.	2.9	28
102	Defining Primary Sclerosing Cholangitis: Results From an International Primary Sclerosing Cholangitis Study Group Consensus Process. Gastroenterology, 2021, 161, 1764-1775.e5.	0.6	28
103	Lysyl oxidase-like protein 2 (LOXL2) modulates barrier function in cholangiocytes in cholestasis. Journal of Hepatology, 2018, 69, 368-377.	1.8	27
104	Analysis of MAdCAM-1 and ICAM-1 polymorphisms in 365 Scandinavian patients with primary sclerosing cholangitis. Journal of Hepatology, 2006, 45, 704-710.	1.8	25
105	Autoreactive monoclonal antibodies from patients with primary biliary cholangitis recognize environmental xenobiotics. Hepatology, 2017, 66, 885-895.	3.6	25
106	Inter- and Intra-individual Variation, and Limited Prognostic Utility, of Serum Alkaline Phosphatase in a Trial of Patients With Primary Sclerosing Cholangitis. Clinical Gastroenterology and Hepatology, 2021, 19, 1248-1257.	2.4	25
107	Primary Biliary Cholangitis: Medical and Specialty Pharmacy Management Update. Journal of Managed Care & Specialty Pharmacy, 2016, 22, S3-S15.	0.5	23
108	Clinical Management of Primary Biliary Cholangitisâ€"Strategies and Evolving Trends. Clinical Reviews in Allergy and Immunology, 2020, 59, 175-194.	2.9	23

#	Article	IF	Citations
109	Immunological Orchestration of Liver Fibrosis. Clinical Reviews in Allergy and Immunology, 2012, 43, 220-229.	2.9	22
110	Development and validation of a primary sclerosing cholangitisâ€“specific patientâ€reported outcomes instrument: The PSC PRO. Hepatology, 2018, 68, 155-165.	3.6	22
111	Obesity in BSB Mice Is Correlated with Expression of Genes for Iron Homeostasis and Leptin. Obesity, 2004, 12, 191-204.	4.0	21
112	RARÎ² acts as both an upstream regulator and downstream effector of miRâ€22 , which epigenetically regulates NUR77 to induce apoptosis of colon cancer cells. FASEB Journal, 2019, 33, 2314-2326.	0.2	21
113	Myeloperoxidase-positive inflammatory cells participate in bile duct damage in primary biliary cirrhosis through nitric oxide-mediated reactions. Hepatology, 2003, 38, 1018-1025.	3.6	21
114	Ascorbic acid reduces the frequency of iron induced micronuclei in bone marrow cells of mice. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2003, 542, 99-103.	0.9	20
115	Cutting Edge Issues in Primary Sclerosing Cholangitis. Clinical Reviews in Allergy and Immunology, 2011, 41, 139-150.	2.9	20
116	Primary Sclerosing Cholangitis Is Not Rare Among Blacks in a Multicenter North American Consortium. Clinical Gastroenterology and Hepatology, 2018, 16, 591-593.	2.4	20
117	Characteristics and Outcomes Reported by Patients With Primary Sclerosing Cholangitis Through an Online Registry. Clinical Gastroenterology and Hepatology, 2019, 17, 1372-1378.	2.4	20
118	Efficacy and Safety of Cenicriviroc in Patients With Primary Sclerosing Cholangitis: PERSEUS Study. Hepatology Communications, 2021, 5, 478-490.	2.0	20
119	Ascorbic Acid Does Not Increase the Oxidative Stress Induced by Dietary Iron in C3H Mice. Journal of Nutrition, 2004, 134, 435-438.	1.3	19
120	GS-02-Efficacy of GKT831 in patients with primary biliary cholangitis and inadequate response to ursodeoxycholic acid: Interim efficacy results of a phase 2 clinical trial. Journal of Hepatology, 2019, 70, e1-e2.	1.8	18
121	Effects of Tumor Necrosis Factor Antagonists in Patients With Primary Sclerosing Cholangitis. Clinical Gastroenterology and Hepatology, 2020, 18, 2295-2304.e2.	2.4	18
122	Polymorphisms in the gene encoding thymus-specific serine protease in the extended HLA complex: a potential candidate gene for autoimmune and HLA-associated diseases. Genes and Immunity, 2002, 3, 306-312.	2.2	17
123	Gene Expression by PBMC in Primary Sclerosing Cholangitis: Evidence for Dysregulation of Immune Mediated Genes. Clinical and Developmental Immunology, 2006, 13, 265-271.	3.3	16
124	Primary sclerosing cholangitis etiopathogenesis and clinical management. Frontiers in Bioscience - Elite, 2012, E4, 1683-1705.	0.9	16
125	Geoepidemiology and changing mortality in primary biliary cholangitis. Journal of Gastroenterology, 2017, 52, 655-662.	2.3	16
126	Electronic Medical Alerts Increase Screening for Chronic Hepatitis B: A Randomized, Double-Blind, Controlled Trial. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 1352-1357.	1.1	16

#	Article	IF	Citations
127	Ursodeoxycholic Acid Treatment Preferentially Improves Overall Survival Among African Americans With Primary Biliary Cholangitis. American Journal of Gastroenterology, 2020, 115, 262-270.	0.2	14
128	A Fibrosisâ€Independent Hepatic Transcriptomic Signature Identifies Drivers of Disease Progression in Primary Sclerosing Cholangitis. Hepatology, 2021, 73, 1105-1116.	3.6	14
129	Immunological potential of cytotoxic T lymphocyte antigen 4 immunoglobulin in murine autoimmune cholangitis. Clinical and Experimental Immunology, 2015, 180, 371-382.	1.1	13
130	Primary Biliary Cholangitis: 2018 Practice Guidance From the American Association for the Study of Liver Diseases. Clinical Liver Disease, 2020, 15, 1-2.	1.0	13
131	Ethnicity-specific alterations of plasma and hepatic lipidomic profiles are related to high NAFLD rate and severity in Hispanic Americans, a pilot study. Free Radical Biology and Medicine, 2021, 172, 490-502.	1.3	13
132	A realâ€world observational cohort of patients with primary biliary cholangitis: TARGETâ€primary biliary cholangitis study design and rationale. Hepatology Communications, 2018, 2, 484-491.	2.0	12
133	Granular Cells as a Marker of Early Amiodarone Hepatotoxicity. Journal of Clinical Gastroenterology, 2000, 31, 241-243.	1.1	12
134	Primary sclerosing cholangitis: etiopathogenesis and clinical management. Frontiers in Bioscience - Elite, 2012, E4, 1683.	0.9	12
135	FISH-Mapped CEPH YACs Spanning 0 to 46 cM on Human Chromosome 6. Genomics, 1996, 36, 104-111.	1.3	11
136	Expression, Genomic Structure and Mapping of the Thymus Specific Protease Prss16: A Candidate Gene for Insulin Dependent Diabetes Mellitus Susceptibility. Journal of Autoimmunity, 2002, 18, 311-316.	3.0	11
137	Prss16 Is Not Required for T-Cell Development. Molecular and Cellular Biology, 2005, 25, 789-796.	1.1	11
138	In situ mass spectrometry of autoimmune liver diseases. Cellular and Molecular Immunology, 2011, 8, 237-242.	4.8	11
139	Endogenous interleukin-22 protects against inflammatory bowel disease but not autoimmune cholangitis in dominant negative form of transforming growth factor beta receptor type II mice. Clinical and Experimental Immunology, 2016, 185, 154-164.	1.1	11
140	Non-Alcoholic Fatty Liver Disease: The New Epidemic and the Need for Novel Nutritional Approaches. Journal of Medicinal Food, 2007, 10, 563-565.	0.8	10
141	Improving Healthcare Systems to Reduce Healthcare Disparities in Viral Hepatitis. Digestive Diseases and Sciences, 2016, 61, 2776-2783.	1.1	10
142	Proposed therapies in primary biliary cholangitis. Expert Review of Gastroenterology and Hepatology, 2016, 10, 371-382.	1.4	10
143	PC.01.8 THE AESOP TRIAL: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY OF OBETICHOLIC ACID IN PATIENTS WITH PRIMARY SCLEROSING CHOLANGITIS. Digestive and Liver Disease, 2018, 50, e67.	0.4	10
144	ILâ€31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASH. Hepatology, 2023, 77, 20-32.	3.6	10

#	Article	IF	Citations
145	The potentiating and protective effects of ascorbate on oxidative stress depend upon the concentration of dietary iron fed C3H mice. Journal of Nutritional Biochemistry, 2007, 18, 272-278.	1.9	9
146	Current Treatment Options for Primary Biliary Cholangitis. Clinics in Liver Disease, 2018, 22, 481-500.	1.0	9
147	Treatment efficacy and safety of seladelpar, a selective peroxisome proliferator-activated receptor delta agonist, in primary biliary cholangitis patients: 12- and 26-week analysis from an ongoing international, randomized, dose raging phase 2 study. Journal of Hepatology, 2018, 68, S105-S106.	1.8	9
148	Methylation signatures in peripheral blood are associated with marked age acceleration and disease progression in patients with primary sclerosing cholangitis. JHEP Reports, 2020, 2, 100060.	2.6	9
149	Electronic health record alerts enhance mass screening for chronic hepatitis B. Scientific Reports, 2020, 10, 19153.	1.6	9
150	Role of Antinuclear Antibodies in Primary Biliary Cholangitis. American Journal of Gastroenterology, 2020, 115, 1604-1606.	0.2	8
151	The use of biologics in the treatment of autoimmune liver disease. Expert Opinion on Investigational Drugs, 2020, 29, 385-398.	1.9	8
152	Interim report of a randomized cross-over study comparing clinical performance of novice trainee endoscopists using conventional air insufflation versus warm water infusion colonoscopy. Journal of Interventional Gastroenterology, 2012, 2, 135-139.	0.1	8
153	Prevalence of Hepatitis B Surface Antigen in US-Born and Foreign-Born Asian/Pacific Islander College Students. Journal of American College Health, 2010, 59, 37-41.	0.8	7
154	Management of symptom complexes in primary biliary cholangitis. Current Opinion in Gastroenterology, 2016, 32, 1.	1.0	7
155	Durability of treatment response after 1 year of therapy with seladelpar in patients with primary biliary cholangitis (PBC): final results of an international phase 2 study. Journal of Hepatology, 2020, 73, S464-S465.	1.8	7
156	Update on New Drugs and Those in Development for the Treatment of Primary Biliary Cholangitis. Gastroenterology and Hepatology, 2018, 14, 154-163.	0.2	7
157	Preventative care in cholestatic liver disease: Pearls for the specialist and subspecialist. Liver Research, 2019, 3, 118-127.	0.5	5
158	Healthcare Disparities Identified Between Hmong and Other Asian Origin Groups Living with Chronic Hepatitis B Infection in Sacramento County 2014â€“2017. Journal of Community Health, 2020, 45, 412-418.	1.9	5
159	Glycomic analysis of antibody indicates distinctive glycosylation profile in patients with autoimmune cholangitis. Journal of Autoimmunity, 2020, 113, 102503.	3.0	5
160	Durable response in the markers of cholestasis through 5 years of open-label extension study of obeticholic acid in primary biliary cholangitis. Digestive and Liver Disease, 2020, 52, e30.	0.4	5
161	Analysis of the IDDM Candidate Gene Prss16 in NOD and NON Mice. Autoimmunity, 2002, 9, 183-186.	0.6	4
162	An adult case of acute lymphoblastic leukaemia presenting as hepatic dysfunction. Digestive and Liver Disease, 2005, 37, 206-210.	0.4	4

#	Article	IF	Citations
163	Iron Metabolism and Related Disorders. , 2013, , 1-41.		4
164	Scratching the surface of cholestatic itch treatments. Hepatology, 2018, 67, 2045-2048.	3.6	4
165	Primary biliary cholangitis: Diagnosis and treatment. Liver Research, 2018, 2, 81-86.	0.5	4
166	Discussion on the role of hemochromatosis susceptibility gene mutation in protecting against iron deficiency in celiac disease. Gastroenterology, 2003, 124, 1562-1563.	0.6	3
167	Obeticholic acid for the treatment of primary biliary cirrhosis. Expert Opinion on Orphan Drugs, 2014, 2, 1351-1358.	0.5	3
168	Human Î²-Defensin 2 in Primary Sclerosing Cholangitis. Clinical and Translational Gastroenterology, 2017, 8, e80.	1.3	3
169	Validity of an Automated Algorithm to Identify Cirrhosis Using Electronic Health Records in Patients with Primary Biliary Cholangitis . Clinical Epidemiology, 2020, Volume 12, 1261-1267.	1.5	3
170	Primary Biliary Cholangitis: A Brief Overview. Clinical Liver Disease, 2020, 15, 100-104.	1.0	3
171	Dynamic Risk Prediction of Response to Ursodeoxycholic Acid Among Patients with Primary Biliary Cholangitis in the USA. Digestive Diseases and Sciences, 2022, 67, 4170-4180.	1.1	3
172	Plasma Oxylipin Profile Discriminates Ethnicities in Subjects with Non-Alcoholic Steatohepatitis: An Exploratory Analysis. Metabolites, 2022, 12, 192.	1.3	3
173	558 - International Experience of Vedolizumab in Primary Sclerosing Cholangitis and Inflammatory Bowel Disease. Gastroenterology, 2018, 154, S-1097.	0.6	2
174	PS-016-Prospective evaluation of serum alkaline phosphatase variability and prognostic utility in primary sclerosing cholangitis using controlled clinical trial data. Journal of Hepatology, 2019, 70, e12-e13.	1.8	2
175	FRI-016-Validation of the PREsTo machine learning algorithm for the prediction of disease progression in patients with primary sclerosing cholangitis. Journal of Hepatology, 2019, 70, e390-e391.	1.8	2
176	PS-122-Seladelpar for the treatment of primary biliary cholangitis: Experience with 26 cirrhotic patients. Journal of Hepatology, 2019, 70, e76.	1.8	2
177	FRI-037-Change in lipids: Characteristics and response to obeticholic acid in TARGET-PBC, a diverse, large United States real-world cohort. Journal of Hepatology, 2019, 70, e400.	1.8	2
178	Glycan biomarkers of autoimmunity and bile acid-associated alterations of the human glycome: Primary biliary cirrhosis and primary sclerosing cholangitis-specific glycans. Clinical Immunology, 2021, 230, 108825.	1.4	2
179	Hepcidin mRNA expression in human liver correlates with serum ferritin. Gastroenterology, 2003, 124, A713.	0.6	1
180	CYTOSKELETAL AUTOANTIBODIES/ANTI-ACTIN ANTIBODIES. , 2007, , 309-316.		1

#	Article	IF	Citations
181	Cytoskeletal Autoantibodies/Antiactin Antibodies. , 2014, , 311-317.		1
182	Primary sclerosing cholangitis: One disease or several?. Clinical Liver Disease, 2014, 3, 34-37.	1.0	1
183	Prevalence of Primary Sclerosing Cholangitis in Black Patients: Results of a Multi-Center North American Consortium. Gastroenterology, 2017, 152, S1185.	0.6	1
184	Primary biliary cholangitis (PBC) in the U.S.: real world effectiveness of obeticholic acid in TARGET-PBC. Journal of Hepatology, 2018, 68, S228-S229.	1.8	1
185	FRI-043-Primary biliary cholangitis-Autoimmune hepatitis overlap syndrome: Characteristics and response to obeticholic acid in TARGET-PBC, a diverse, large United States real-world cohort. Journal of Hepatology, 2019, 70, e403.	1.8	1
186	Epidemiology and Natural History of Primary Sclerosing Cholangitis. , 2017, , 1-11.		1
187	Primary Biliary Cholangitis. , 2020, , 335-357.		1
188	Su1299 Interim Report of a Randomized Cross-Over Study Comparing Clinical Performance of Novice Trainee Endoscopists Using Conventional Air Insufflation Versus Warm Water Infusion Colonoscopy. Gastrointestinal Endoscopy, 2012, 75, AB284-AB285.	0.5	0
189	694 LYSYL OXIDASE-LIKE 2 (LOXL2) PROTEIN IS INDUCED IN HUMAN CHOLESTATIC LIVER DISEASE AND IN ANIMAL MODELS OF CHOLANGIOPATHIES. Journal of Hepatology, 2013, 58, S281-S282.	1.8	0
190	p53 Autoantibodies. , 2014, , 289-294.		0
191	P359 SERUM Î²-DEFENSIN 2 IS INCREASED IN PRIMARY SCLEROSING CHOLANGITIS AND CORRELATES WITH DEFB4 GENE COPY NUMBER. Journal of Hepatology, 2014, 60, S187.	1.8	0
192	Randomized-Controlled Trial Comparing Adenoma Detection Rate Using Water Exchange Versus Air Insufflation Colonoscopy in a U.S. Community-Based Setting. American Journal of Gastroenterology, 2015, 110, S643-S644.	0.2	0
193	Capsule Commentary on Mukhtar et al., Assessment of HBV Preventive Services in a Medically Underserved Asian and Pacific Islander Population Using Provider and Patient Data. Journal of General Internal Medicine, 2015, 30, 866-866.	1.3	0
194	Primary Biliary Cholangitis: Its Science and Practice. , 2017, , 129-182.		0
195	PS-012-Validation of histologic and non-invasive measures of fibrosis as surrogate end points of disease progression in patients with primary sclerosing cholangitis. Journal of Hepatology, 2019, 70, e10-e11.	1.8	0
196	THU-024-Methylation signatures in blood show accelerated epigenetic aging in patients with primary sclerosing cholangitis compared to healthy controls. Journal of Hepatology, 2019, 70, e170.	1.8	0
197	FRI-033-Long-term obeticholic acid treatment is associated with improvements in collagen morphometry in patients with primary biliary cholangitis. Journal of Hepatology, 2019, 70, e398.	1.8	0
198	FRI-438-Histone deacetylase 5 methylation changes in mice and patients with Wilson disease. Journal of Hepatology, 2019, 70, e587.	1.8	0

#	Article	IF	Citations
199	OC.01.4 THREE YEARS OF OBETICHOLIC ACID (OCA) THERAPY RESULTS IN HISTOLOGICAL IMPROVEMENTS IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS: FURTHER ANALYSIS OF THE POISE BIOPSY SUBSTUDY. Digestive and Liver Disease, 2019, 51, e78.	0.4	0
200	764 â€“ Protein and Mirna Profiling of Circulating Extracellular Vesicles in Patients with Primary Sclerosing Cholangitis. Gastroenterology, 2019, 156, S-1213.	0.6	0
201	PTU-009â€…Long-term effects of obeticholic acid in patients with primary biliary cholangitis on inflammatory markers. , 2019, , .		0
202	ATU-09â€…Obeticholic acid treatment is associated with improved collagen morphometry in patients with primary biliary cholangitis. , 2019, , .		0
203	Editorial: biochemical responses do not tell the whole story in primary biliary cholangitis. Alimentary Pharmacology and Therapeutics, 2020, 51, 177-178.	1.9	0
204	Bugs in Bile: A Fly in the Ointment?. Liver Transplantation, 2020, 26, 1571-1572.	1.3	0
205	Psychometric evaluation of the adult itch reported outcome tool, a worst-itch numeric rating scale in adults with cholestatic liver disease. Journal of Hepatology, 2020, 73, S463.	1.8	0
206	Serum bile acid species are associated with liver fibrosis and clinical disease progression in patients with primary sclerosing cholangitis. Journal of Hepatology, 2020, 73, S482-S483.	1.8	0
207	Removal of fibrosis-related genes identifies a hepatic gene expression signature that identifies canonical signaling pathways and is correlated with clinical outcomes in patients with primary sclerosing cholangitis. Journal of Hepatology, 2020, 73, S483-S484.	1.8	0
208	Hepatic transcriptomic analysis identifies a mast cell gene expression signature that correlates with fibrosis stage and is prognostic in patients with primary sclerosing cholangitis. Journal of Hepatology, 2020, 73, S484.	1.8	0
209	Relationship between Primary Biliary Cirrhosis and Lipoic Acid. Oxidative Stress and Disease, 2008, , .	0.3	0
210	Use of Cracker Swallow for Detection of Motility Abnormality on High-Resolution Manometry. American Journal of Gastroenterology, 2008, 103, S36-S37.	0.2	0
211	A Rare Case of Spontaneous Cryptococcal Peritonitis. American Journal of Gastroenterology, 2008, 103, S242.	0.2	0
212	Diagnostic Liver Immunology. , 2014, , 45-53.		0
213	Primary and Secondary Sclerosing Cholangitis. , 2018, , 626-647.e6.		0
214	Diagnostic Liver Immunology. , 2020, , 139-150.		0
215	Tumor Immunology. , 2007, , 137-149.		0
216	S0984â€ƒLong-Term Efficacy and Safety of Obeticholic Acid in Patients With Primary Biliary Cholangitis: A Demographic Subgroup Analysis of 5-Year Results From the POISE Trial. American Journal of Gastroenterology, 2020, 115, S501-S502.	0.2	0

#	Article	IF	Citations
217	Statins, Fibrates, and Other Peroxisome Proliferator-Activated Receptor Agonists for the Treatment of Cholestatic Liver Diseases. Gastroenterology and Hepatology, 2020, 16, 31-38.	0.2	0